CPI-refractory tumors – Talk Bio

Actionable Insights Powered by AI

CatalYm Presents Long-Term Phase 1/2a Data for Visugromab at ESMO 2025

4 days ago talkbio0Tagged CatalYm, CPI-refractory tumors, ESMO, Growth Differentiation Factor 15, Visugromab

CatalYm; Visugromab; ESMO 2025; CPI-Refractory Tumors; GDF-15